NO20064306L - Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer - Google Patents

Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer

Info

Publication number
NO20064306L
NO20064306L NO20064306A NO20064306A NO20064306L NO 20064306 L NO20064306 L NO 20064306L NO 20064306 A NO20064306 A NO 20064306A NO 20064306 A NO20064306 A NO 20064306A NO 20064306 L NO20064306 L NO 20064306L
Authority
NO
Norway
Prior art keywords
inhibitors
lactams
present
conformationally restricted
peptidomimetic inhibitors
Prior art date
Application number
NO20064306A
Other languages
English (en)
Inventor
William W Bachovchin
Hung-Sen Lai
Wengen Wu
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of NO20064306L publication Critical patent/NO20064306L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Foreliggende oppfinnelse omhandler inhibitorer av post-prolin spaltende enzym, så som inhibitorer av dipeptidyl peptidase IV, så vel som farmasøytiske preparater derav og fremgangsmåter for anvendelse av slike-inhibitorer. Spesielt inkorporerer inhibitorene ifølge foreliggende oppfinnelse en laktamring i ryggraden av inhibito-rene. Forbindelsene ifølge foreliggende oppfinnelse kan ha en bedre terapeutisk indeks, som delvis skyldes redusert toksisitet og/eller forbedret spesifisitet for den målsøkte protease.
NO20064306A 2004-02-23 2006-09-22 Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer NO20064306L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54722604P 2004-02-23 2004-02-23
PCT/US2005/006127 WO2005082849A1 (en) 2004-02-23 2005-02-23 Lactams as conformationally constrained peptidomimetic inhibitors

Publications (1)

Publication Number Publication Date
NO20064306L true NO20064306L (no) 2006-11-17

Family

ID=34910873

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064306A NO20064306L (no) 2004-02-23 2006-09-22 Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer

Country Status (11)

Country Link
US (1) US20090209491A1 (no)
EP (1) EP1732885A1 (no)
JP (1) JP2007526255A (no)
CN (1) CN101090885A (no)
AU (1) AU2005217642B2 (no)
BR (1) BRPI0507971A (no)
CA (1) CA2555961A1 (no)
IL (1) IL177643A (no)
MX (1) MXPA06009588A (no)
NO (1) NO20064306L (no)
WO (1) WO2005082849A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
JP5072848B2 (ja) * 2005-09-20 2012-11-14 ノバルティス アーゲー 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
WO2007078726A2 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2010106441A2 (en) * 2009-03-20 2010-09-23 Centre Hospitalier Universitaire Sainte-Justine Peptidomimetics for modulating interleukin-1 receptor
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2571864A1 (en) 2010-05-17 2013-03-27 Array Biopharma, Inc. Piperidinyl-substituted lactams as gpr119 modulators
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140256756A1 (en) * 2011-11-03 2014-09-11 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
CN112986065B (zh) * 2021-02-08 2021-08-31 杭州同创医学检验实验室有限公司 一种用于血细胞分析仪的全血质控品及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247698B (it) * 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
AU7699898A (en) * 1997-05-28 1998-12-30 Cadus Pharmaceutical Corporation Conformationally constrained peptidomimetics as beta-turn templates and modulators of sh3 domains
DE19841895A1 (de) * 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US6511973B2 (en) * 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US20030040534A1 (en) * 2001-04-16 2003-02-27 Hughes David E. Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
ES2291477T3 (es) * 2001-06-27 2008-03-01 Smithkline Beecham Corporation Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
JP4266092B2 (ja) * 2001-10-09 2009-05-20 第一三共株式会社 ジアミン誘導体
GB0130285D0 (en) * 2001-12-19 2002-02-06 Astrazeneca Ab Chemical process
EP1489088B1 (en) * 2002-03-25 2008-08-13 Nippon Kayaku Kabushiki Kaisha Novel alpha-amino-n-(diaminophosphinyl)lactam derivative
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US7112702B2 (en) * 2002-12-12 2006-09-26 General Electric Company Process for the synthesis of bisphenol
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists

Also Published As

Publication number Publication date
IL177643A (en) 2011-11-30
JP2007526255A (ja) 2007-09-13
WO2005082849A1 (en) 2005-09-09
IL177643A0 (en) 2006-12-31
EP1732885A1 (en) 2006-12-20
AU2005217642A1 (en) 2005-09-09
US20090209491A1 (en) 2009-08-20
MXPA06009588A (es) 2007-03-30
AU2005217642B2 (en) 2012-04-12
CA2555961A1 (en) 2005-09-09
BRPI0507971A (pt) 2007-07-24
WO2005082849A8 (en) 2005-11-10
CN101090885A (zh) 2007-12-19

Similar Documents

Publication Publication Date Title
NO20064306L (no) Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer
WO2003045977A3 (en) Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
GEP20094679B (en) Dipeptidyl peptidase inhibitors
NO20064307L (no) Inhibitorer av dipeptidylpeptidase IV for regulering av glukose metabolisme
HK1086265A1 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
IS7817A (is) Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki.
EP1624874A4 (en) 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IN THE TREATMENT OR PREVENTION OF DIABETES
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
EP1490335A4 (en) HETEROCYCLIC BETA-AMINO DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
HU0302788D0 (en) New compounds
EP1635818A4 (en) CONDENSED INDOLE AS A DIPEPTIDYL-PEPTIDASE INHIBITOR FOR THE TREATMENT OR PREVENTION OF DIABETES
TNSN08367A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1554256A4 (en) INHIBITORS OF PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE USEFUL IN THE TREATMENT OF DIABETES
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
EP1796669A4 (en) AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1554280A4 (en) ANTIDIABETIC HETEROCYCLIC BETA AMINO BINDINGS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE
EP1888066A4 (en) AMINOCYCLOHEXANES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1651623A4 (en) HEXAHYDRODIAZEPINONES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OR PREVENTION OF DIABETES
MX2009002740A (es) Inhibidores de renina.
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
MY138965A (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
TW200500338A (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JO2396B1 (en) Peptidase de peptidyltransferase inhibitors amino builder for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application